Pharsight

1. Altace patents expiration

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7368469	KING PFIZER	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events	Aug, 2020 (3 years ago)

Market Authorisation Date: 27 February, 2007

Treatment: Method of reducing risk of myocardial infarction, stroke and death

Dosage: TABLET;ORAL

Strength	Dosage	Availability
5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
1.25MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
2.5MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued
10MG Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons	TABLET;ORAL	Discontinued

Drug Patent Number	Company	Drug Patent Title	Drug Patent Expiry	Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7368469	KING PHARMS LLC	Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events	Aug, 2020 (3 years ago)

Market Authorisation Date: 28 January, 1991

Treatment: Method of reducing risk of myocardial infarction, stroke and death

Dosage: CAPSULE;ORAL